B-intervention	0	8	Physical
I-intervention	9	17	Activity
O	18	21	for
O	22	29	Symptom
O	30	40	Management
O	41	43	in
O	44	49	Women
O	50	54	With
O	55	65	Metastatic
O	66	72	Breast
O	73	79	Cancer
O	79	80	:
O	81	82	A
O	83	93	Randomized
O	94	105	Feasibility
O	106	111	Trial
O	112	114	on
O	115	123	Physical
O	124	132	Activity
O	133	136	and
O	137	143	Breast
O	144	154	Metastases
O	154	155	.

O	156	164	Physical
O	165	173	activity
O	174	177	for
O	178	183	women
O	184	188	with
O	189	194	early
O	194	195	-
O	195	200	stage
O	201	207	breast
O	208	214	cancer
O	215	217	is
O	218	222	well
O	223	233	recognized
O	234	237	for
O	238	246	managing
O	247	253	cancer
O	253	254	-
O	254	261	related
O	262	270	symptoms
O	271	274	and
O	275	284	improving
O	285	292	quality
O	293	295	of
O	296	300	life
O	300	301	.

O	302	307	While
O	308	317	typically
O	318	326	excluded
O	327	331	from
O	332	345	interventions
O	345	346	,
O	347	352	women
O	353	357	with
O	358	368	metastatic
O	369	375	breast
O	376	382	cancer
O	383	386	may
O	387	391	also
O	392	399	benefit
O	400	404	from
O	405	413	physical
O	414	422	activity
O	422	423	.

O	424	426	To
O	427	428	1
O	428	429	)
O	430	439	determine
O	440	443	the
O	444	450	safety
O	451	454	and
O	455	466	feasibility
O	467	469	of
O	470	471	a
O	472	480	physical
O	481	489	activity
O	490	497	program
O	498	501	for
O	502	507	women
O	508	512	with
O	513	523	metastatic
O	524	530	breast
O	531	537	cancer
O	538	541	and
O	542	543	2
O	543	544	)
O	545	552	explore
O	553	556	the
O	557	565	efficacy
O	566	568	of
O	569	572	the
O	573	580	program
O	580	581	.

B-total-participants	582	590	Fourteen
B-eligibility	591	596	women
I-eligibility	597	601	with
I-eligibility	602	612	metastatic
I-eligibility	613	619	breast
I-eligibility	620	626	cancer
O	627	631	were
O	632	642	randomized
O	643	645	to
O	646	652	either
O	653	654	a
B-control	655	662	control
I-control	663	668	group
O	669	671	or
O	672	674	an
O	675	676	8
O	676	677	-
O	677	681	week
O	682	686	home
O	686	687	-
O	687	692	based
O	693	701	physical
O	702	710	activity
O	711	723	intervention
O	724	734	comprising
O	735	740	twice
O	741	747	weekly
O	748	758	supervised
O	759	769	resistance
O	770	778	training
O	779	782	and
O	783	785	an
O	786	798	unsupervized
O	799	806	walking
O	807	814	program
O	814	815	.

O	816	819	The
O	820	831	recruitment
O	832	836	rate
O	837	840	was
O	841	843	93
O	843	844	%
O	844	845	.

B-outcome	846	855	Adherence
O	856	858	to
O	859	862	the
O	863	873	resistance
O	874	877	and
O	878	885	walking
O	886	896	components
O	897	899	of
O	900	903	the
O	904	911	program
O	912	915	was
B-iv-bin-percent	916	919	100
I-iv-bin-percent	919	920	%
O	921	924	and
B-iv-bin-percent	925	927	25
I-iv-bin-percent	927	928	%
O	928	929	,
O	930	942	respectively
O	942	943	.

B-outcome	944	946	No
I-outcome	947	954	adverse
I-outcome	955	961	events
O	962	966	were
O	967	975	reported
O	975	976	.

O	977	981	When
O	982	986	mean
O	987	993	change
O	994	1000	scores
O	1001	1005	from
O	1006	1014	baseline
O	1015	1017	to
O	1018	1034	postintervention
O	1035	1039	were
O	1040	1048	compared
O	1048	1049	,
O	1050	1056	trends
O	1057	1059	in
O	1060	1065	favor
O	1066	1068	of
O	1069	1072	the
O	1073	1081	exercise
O	1082	1087	group
O	1088	1092	over
O	1093	1096	the
O	1097	1104	control
O	1105	1110	group
O	1111	1115	were
O	1116	1124	observed
O	1125	1128	for
O	1129	1132	the
B-outcome	1133	1143	Functional
I-outcome	1144	1154	Assessment
I-outcome	1155	1157	of
I-outcome	1158	1165	Chronic
I-outcome	1166	1173	Illness
I-outcome	1174	1181	Therapy
I-outcome	1181	1182	-
I-outcome	1182	1189	Fatigue
I-outcome	1190	1195	score
O	1196	1197	(
B-iv-cont-mean	1197	1198	+
I-iv-cont-mean	1198	1199	5
I-iv-cont-mean	1199	1200	.
I-iv-cont-mean	1200	1201	6
O	1202	1203	±
B-iv-cont-sd	1204	1205	3
I-iv-cont-sd	1205	1206	.
I-iv-cont-sd	1206	1207	2
O	1208	1210	vs
O	1210	1211	.
B-cv-cont-mean	1212	1213	-
I-cv-cont-mean	1213	1214	1
I-cv-cont-mean	1214	1215	.
I-cv-cont-mean	1215	1216	8
O	1217	1218	±
B-cv-cont-sd	1219	1220	3
I-cv-cont-sd	1220	1221	.
I-cv-cont-sd	1221	1222	9
O	1222	1223	,
O	1224	1236	respectively
O	1236	1237	)
O	1237	1238	,
B-outcome	1239	1245	VO2max
O	1246	1247	(
B-iv-cont-mean	1247	1248	+
I-iv-cont-mean	1248	1249	1
I-iv-cont-mean	1249	1250	.
I-iv-cont-mean	1250	1251	6
I-iv-cont-mean	1252	1254	ml
I-iv-cont-mean	1254	1255	/
I-iv-cont-mean	1255	1257	kg
I-iv-cont-mean	1257	1258	/
I-iv-cont-mean	1258	1264	minute
O	1265	1266	±
B-iv-cont-sd	1266	1267	1
I-iv-cont-sd	1267	1268	.
I-iv-cont-sd	1268	1269	8
I-iv-cont-sd	1270	1272	mL
I-iv-cont-sd	1272	1273	/
I-iv-cont-sd	1273	1275	kg
I-iv-cont-sd	1275	1276	/
I-iv-cont-sd	1276	1282	minute
O	1283	1285	vs
O	1285	1286	.
B-cv-cont-mean	1287	1288	-
I-cv-cont-mean	1288	1289	0
I-cv-cont-mean	1289	1290	.
I-cv-cont-mean	1290	1291	2
I-cv-cont-mean	1292	1294	mL
I-cv-cont-mean	1294	1295	/
I-cv-cont-mean	1295	1297	kg
I-cv-cont-mean	1297	1298	/
I-cv-cont-mean	1298	1304	minute
O	1305	1306	±
B-cv-cont-sd	1306	1307	0
I-cv-cont-sd	1307	1308	.
I-cv-cont-sd	1308	1309	1
I-cv-cont-sd	1310	1312	mL
I-cv-cont-sd	1312	1313	/
I-cv-cont-sd	1313	1315	kg
I-cv-cont-sd	1315	1316	/
I-cv-cont-sd	1316	1322	minute
O	1322	1323	,
O	1324	1336	respectively
O	1336	1337	)
O	1338	1341	and
B-outcome	1342	1345	six
I-outcome	1345	1346	-
I-outcome	1346	1352	minute
I-outcome	1353	1357	walk
I-outcome	1358	1362	test
O	1363	1364	(
B-iv-cont-mean	1364	1365	+
I-iv-cont-mean	1365	1367	40
I-iv-cont-mean	1368	1369	m
O	1370	1371	±
B-iv-cont-sd	1372	1374	23
I-iv-cont-sd	1375	1376	m
O	1377	1379	vs
O	1379	1380	.
B-cv-cont-mean	1381	1382	-
I-cv-cont-mean	1382	1384	46
I-cv-cont-mean	1385	1386	m
O	1387	1388	±
B-cv-cont-sd	1389	1391	56
I-cv-cont-sd	1392	1393	m
O	1393	1394	,
O	1395	1407	respectively
O	1407	1408	)
O	1408	1409	.

O	1410	1411	A
O	1412	1421	partially
O	1422	1432	supervised
O	1433	1437	home
O	1437	1438	-
O	1438	1443	based
O	1444	1452	physical
O	1453	1461	activity
O	1462	1469	program
O	1470	1473	for
O	1474	1479	women
O	1480	1484	with
O	1485	1495	metastatic
O	1496	1502	breast
O	1503	1509	cancer
O	1510	1512	is
B-outcome	1513	1521	feasible
I-outcome	1522	1525	and
I-outcome	1526	1530	safe
O	1530	1531	.

O	1532	1535	The
O	1536	1540	dose
O	1541	1543	of
O	1544	1547	the
O	1548	1558	resistance
O	1559	1567	training
O	1568	1577	component
O	1578	1581	was
B-outcome	1582	1586	well
I-outcome	1587	1596	tolerated
O	1597	1600	and
O	1601	1611	achievable
O	1612	1614	in
O	1615	1619	this
O	1620	1630	population
O	1630	1631	.

O	1632	1634	In
O	1635	1643	contrast
O	1643	1644	,
O	1645	1654	adherence
O	1655	1658	and
O	1659	1669	compliance
O	1670	1672	to
O	1673	1676	the
O	1677	1684	walking
O	1685	1692	program
O	1693	1697	were
O	1698	1702	poor
O	1702	1703	.

O	1704	1715	Preliminary
O	1716	1720	data
O	1721	1728	suggest
O	1729	1730	a
O	1731	1739	physical
O	1740	1748	activity
O	1749	1756	program
O	1756	1757	,
O	1758	1768	comprising
O	1769	1782	predominantly
O	1783	1793	resistance
O	1794	1802	training
O	1802	1803	,
O	1804	1807	may
O	1808	1812	lead
O	1813	1815	to
O	1816	1828	improvements
O	1829	1831	in
O	1832	1840	physical
O	1841	1849	capacity
O	1850	1853	and
O	1854	1857	may
O	1858	1862	help
O	1863	1868	women
O	1869	1871	to
O	1872	1876	live
O	1877	1881	well
O	1882	1886	with
O	1887	1892	their
O	1893	1900	disease
O	1900	1901	.
